Advancing Predictive Biomarker Development through Digital Pathology Integration
Dr. Mariam Gachechiladze's research contributes to the strategic initiatives in digital pathology and oncology, including the Swiss Digital Pathology Initiative (SDPI), BMI2/Loop and Swiss Personalized Oncology National data Stream (SPO-NDS) at the Institute of Pathology and Molecular Pathology, University of Zurich. Her work is primarily focused on the identification and validation of predictive biomarker combinations for the development of personalized therapy approaches in cancer patients, specifically for the combination therapies involving standard DNA-damaging agents, DNA damage response targeted small molecule inhibitors, and immunotherapy.
Key Papers
Tspan6 stimulates the chemoattractive potential of breast cancer cells for B cells in an EV- and LXR-dependent manner.
Molostvov G, Gachechiladze M, Shaaban AM, Hayward S, Dean I, Dias IHK, Badr N, Danial I, Mohammed F, Novitskaya V, Paniushkina L, Speirs V, Hanby A, Nazarenko I, Withers DR, van Laere S, Long HM, Berditchevski F.
Cell Rep. 2023 Mar 28;42(3):112207. doi: 10.1016/j.celrep.2023.112207. Epub 2023 Mar 3.
A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression.
Rigamonti N, Veitonmäki N, Domke C, Barsin S, Jetzer S, Abdelmotaleb O, Bessey R, Lekishvili T, Malvezzi F, Gachechiladze M, Behe M, Levitsky V, Trail PA.
Cancer Immunol Res. 2022 May 3;10(5):626-640. doi: 10.1158/2326-6066.CIR-21-0553.
Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors.
Gachechiladze M, Skarda J, Bouchalova K, Soltermann A, Joerger M.
Front Oncol. 2020 Nov 3;10:581217. doi: 10.3389/fonc.2020.581217.
Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma.
Gachechiladze M, Škarda J, Skanderová D, Überall I, Kolek V, Smičkova P, Vojta P, Vbrková J, Hajdúch M, Shani I, Kolář Z, Stahel R, Weder W, Rulle U, Soltermann A, Joerger M.
Lung Cancer. 2020 Sep;147:30-38. doi: 10.1016/j.lungcan.2020.06.025. Epub 2020 Jun 23.
The CD151-midkine pathway regulates the immune microenvironment in inflammatory breast cancer.
Hayward S, Gachechiladze M, Badr N, Andrijes R, Molostvov G, Paniushkina L, Sopikova B, Slobodová Z, Mgebrishvili G, Sharma N, Horimoto Y, Burg D, Robertson G, Hanby A, Hoar F, Rea D, Eckhardt BL, Ueno NT, Nazarenko I, Long HM, van Laere S, Shaaban AM, Berditchevski F.
J Pathol. 2020 May;251(1):63-73. doi: 10.1002/path.5415. Epub 2020 Mar 24.
Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
Majera D, Skrott Z, Bouchal J, Bartkova J, Simkova D, Gachechiladze M, Steigerova J, Kurfurstova D, Gursky J, Korinkova G, Cwiertka K, Hodny Z, Mistrik M, Bartek
J. Prostate. 2019 Mar;79(4):352-362. doi: 10.1002/pros.23741. Epub 2018 Nov 29.
Teaching
Past teaching activity at Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic:
- Teaching of the subjects Molecular Pathology and Methodological Foundations of Pathology
- Predictive and prognostic pathology: introduction to basic methods of prognosis and prediction in classic pathology and cytopathology, predictive and prognostic biomarkers based on classic diagnostic criteria and immunohistochemistry, limitations of histopathology and immunohistochemistry, predictive and prognostic biomarker discovery by molecular pathology and their clinical implementation, specialised predictive and prognostic pathology of lung and breast cancers.
- Study Blocks:
- PAT/VCB31 and VAB31 Molecular Pathology Study Program: General Human Medicine (Czech program VCB31, International program VAB31) 3rd year, 6th Semester (teaching years 2012 - 2020)
- PAT/VCB41 Methodological Foundations of Pathology Study Program: General Human Medicine (Czech program), 2nd year, 5th Semester – (teaching years 2013 - 2020)
- LRR/MOPA Molecular Pathology, Clinical Application Study Program: Experimental Biology PrF UP, 4/5th year, spring semester (teaching years 2016 - 2020)